Leerink Partners analyst Mani Foroohar has maintained their bullish stance on RGNX stock, giving a Buy rating yesterday.
Mani Foroohar has given his Buy rating due to a combination of factors that position RegenXBio favorably in the market. The recent safety concerns surrounding a competitor’s product, Elevidys, have highlighted the importance of a strong risk/benefit profile, which RegenXBio appears to possess.
RegenXBio’s use of a different AAV capsid and transgene, along with a clean safety record in their current trials, sets them apart. Additionally, the company’s encouraging efficacy results to date support a positive outlook. These elements combined suggest a promising opportunity for RegenXBio to capture market share, justifying the Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.